Stimgenics Open-Label, Post Market Study

Chronic Low Back Pain Clinical Trial

— SGX-SCS-RCT  

Official title:

Stimgenics Open-Label, Post Market Study: A Clinical Trial to Study the Effects of Stimgenics Spinal Cord Stimulation (SGX-SCS) Programs in Treating Intractable Chronic Back Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03606187
• Other study ID #: SGEN-2018PM2
• Status: Completed
• Phase: N/A
• Start date: June 26, 2018
• Est. completion date: July 22, 2020

Study information

• Verified date: February 2021
• Source: Stimgenics LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this investigational study is to study the effects of Stimgenics Spinal Cord Stimulation (SGX-SCS) in subjects with chronic, intractable pain of the trunk with lower limb pain, including unilateral or bilateral pain associated with the following conditions: failed back surgery syndrome, intractable low back pain and leg pain.

Description:

This is an open-label prospective, randomized, controlled, multi-center study comparing Stimgenics Spinal Cord Stimulation (SGX-SCS) programming approach to Standard SCS programming approach.

Subjects meeting study entrance criteria will be randomized in a 1:1 ratio to one of two study treatment groups:

• Test treatment group with SGX-SCS programming approach

• Control treatment group with Standard SCS programming approach

Data at follow-up visits will be compared between the two treatment groups, and in reference to baseline assessments collected at the beginning of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: July 22, 2020
• Est. primary completion date: November 8, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Be a candidate for SCS system (trial and implant) per labeled indication (back and leg pain)

2. Has an average back pain intensity = 5.0 cm on the 10.0 cm Visual Analog Scale (VAS) at the time of enrollment with moderate to severe chronic leg pain

3. Be willing and capable of giving written informed consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided.

4. Be willing and capable of subjective evaluation, read and understand English-written questionnaires, and read, understand and sign the written inform consent in English.

5. Be 18 years of age or older at the time of enrollment

6. Be on a stable pain medication regime, as determined by the study investigator, for at least 30 days prior to enrolling in this study

7. Be willing to not increase pain medications from baseline through the 3-Month Visit

8. Be willing and able to comply with study-related requirements, procedures, and visits

Exclusion Criteria:

1. Has a medical, anatomical, and/or psychosocial condition that is contraindicated for commercially available IntellisTM SCS systems as determined by the Investigator

2. Be concurrently participating in another clinical study

3. Has an existing active implanted device such as a pacemaker, another SCS unit, peripheral nerve stimulator, and/or drug delivery pump, etc.

4. Has pain in other area(s) and/or medical condition requiring the regular use of significant pain medications that could interfere with accurate pain reporting, study procedures, and/or confound evaluation of study endpoints, as determined by the Investigator

5. Has mechanical spine instability as determined by the Investigator

Related Conditions & MeSH terms

• Back Pain
• Chronic Low Back Pain
• Low Back Pain

Intervention

Device:
• Stimgenics SCS Programming Approach
Stimgenics SCS Programming approach Using Intellis(TM) SCS system
• Standard SCS Programming Approach
Standard SCS Programming approach using Intellis(TM) SCS system

Locations

Country	Name	City	State
United States	StimGenics	Bloomington	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Stimgenics LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Percentage of Individual Responders	Percentage of Participants with a 50% decrease in back pain at 3 months compared to baseline. Pain rating will be measured on the 10 cm Visual Analog Scale (VAS). Change in back pain score will be used to determine individual responder (e.g., 50% reduction in VAS compared to Baseline VAS).	3 months
Secondary	Percentage of Individual Responders	The percentage of Individual Responders (50% reduction in pain score rated on a Visual Analog Scale); Test for superiority	3 months
Secondary	Change in Back Pain Score	Comparison of change from Baseline in back pain score (using Visual Analog Scale 0.0-10.0cm) determined at the 3- and 6-month visit after device activation, between test and control in a statistical test of non-inferiority. This is calculated as: Change from Baseline in Back Pain VAS = 3-Month Visit Pain VAS - Baseline Pain VAS.	3 months
Secondary	6 Months Comparison of Back Pain Treatment Success	Comparison of Back Pain Treatment Success (responder rate), measured as subjects with at least a 50% reduction in Back Pain Visual Analog Scale (VAS), evaluated at 6 months after device activation, between test and control	6 months
Secondary	Oswestry Disability Index (ODI)	Oswestry Disability Index (ODI) evaluated at 3 months visit	3 months
Secondary	Adverse Events	Frequency of treatment emergent adverse events	3 months